5241642026-09-095241642026-09-09in-capmkt:CapacityAdditionMemberiso4217:INRIOLCPIOL Chemicals and Pharmaceuticals Limited524164NOTLISTEDINE485C01029Capacity addition/Product launch (Sub-para 3-Para B)Capacity additionNewfalse2026-09-0914:30:002026-09-0912000 MTPA95%6000 MTPAExpected to be commercialized by December 20273500000000Internal AccrualsThe capacity expansion is being undertaken to address the growing global demand for Ibuprofen and reinforce the Company’s established position as a leading global manufacturer of Ibuprofen. The expansion is also aligned with the ongoing business development and customer engagements across various international markets, reflecting increasing opportunities for the Company’s Ibuprofen business. Supported by its backward-integrated manufacturing platform, established global customer base and proven manufacturing capabilities, the additional capacity will enhance the Company’s ability to meet evolving customer requirements, strengthen supply reliability and support long-term growth in the Ibuprofen business